Meeting of the National Vaccine Advisory Committee, 37817-37818 [2013-14996]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 121 / Monday, June 24, 2013 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
appoint a divestiture trustee, if it brings
an action against Respondents pursuant
to Section 5(l) of the FTC Act. The
Order also governs the divestiture
trustee’s duties, privileges, and powers.
The Order requires Respondents, or
the divestiture trustee, if appointed, to
file periodic reports detailing efforts to
divest the Tesoro Terminal and the
status of that undertaking. Commission
representatives may gain reasonable
access to Respondents’ business records
related to compliance with the consent
agreement. The Order terminates ten
(10) years after its issuance.
V. The Order to Maintain Assets
The Order to Maintain Assets seeks to
preserve the Tesoro Terminal as a
viable, competitive, ongoing business,
and to ensure that Respondents do not
access the confidential business
information belonging to this business.
Respondents agree to preserve the
Tesoro Terminal in substantially the
same condition existing at the time
when Respondents executed the
Consent Agreement. Pursuant to the
Order to Maintain Assets, Respondents
will provide the Tesoro Terminal with
sufficient financial and other resources
to maintain current operation levels and
carry already planned capital and
improvement projects.
The Order to Maintain Assets also
empowers the Commission to appoint a
monitor to oversee Respondents’
compliance with their obligations under
the Order. The Order to Maintain Assets
outlines the rights, duties, and
responsibilities of the monitor,
including access to business records,
hiring necessary consultants and
attorneys, and any other thing
reasonably necessary to carry out their
duties. The Order to Maintain Assets
further prohibits Respondents from
interfering with the monitor’s
obligations and requires them to
indemnify the monitor.
The monitor shall submit periodic
reports to the Commission concerning
compliance with the Order to Maintain
Assets. The Commission may appoint a
different monitor if the original monitor
fails to carry out his duties. The Order
to Maintain Assets terminates either (1)
three days after the Commission
withdraws its acceptance of the Consent
Agreement or (2) three days after the
monitor completes its final report
required by Paragraph V.C.(ii) of this
Order to Maintain Assets.
VI. Opportunity for Public Comment
The proposed Consent Agreement has
been placed on the public record for
thirty (30) days for receipt of comments
by interested persons. The Commission
VerDate Mar<15>2010
18:13 Jun 21, 2013
Jkt 229001
has also issued its Complaint in this
matter. Comments received during this
comment period will become part of the
public record. After thirty (30) days, the
Commission will again review the
proposed Consent Agreement and the
comments received and will decide
whether it should withdraw from the
Consent Agreement, modify it, or make
final the proposed Order.
By accepting the proposed Consent
Agreement subject to final approval, the
Commission anticipates that the
competitive problems alleged in the
Complaint will be resolved. The
purpose of this analysis is to invite
public comment on the proposed Order
to aid the Commission in its
determination of whether it should
make final the proposed Order
contained in the Agreement. This
analysis is not intended to constitute an
official interpretation of the proposed
Order, nor is it intended to modify the
terms of the proposed Order in any way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2013–14923 Filed 6–21–13; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Vaccine
Advisory Committee
National Vaccine Program
Office, Office of the Assistant Secretary
for Health, Office of the Secretary,
Department of Health and Human
Services.
ACTION: Notice of a teleconference
meeting.
AGENCY:
SUMMARY: As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that the National Vaccine Advisory
Committee (NVAC) will be holding a
special meeting. This meeting will be
held utilizing a means of virtual
technology; the meeting will be
conducted as an audio telephone
conference call. The meeting will be
open to the public. Individuals may call
in to attend this virtual meeting. A
public comment session will be
provided. Participation in this meeting
is limited to 60 people. Therefore, preregistration is required for both public
participation and comment. Individuals
who wish to participate in the meeting
by audio telephone conference call and/
or provide public comment should preregister by sending an email to
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
37817
nvpo@hhs.gov or calling (202) 690–
5566. Individuals will be required to
provide their name, organization, and
email address to pre-register. The
meeting agenda will be posted on the
NVAC Web site at https://www.hhs.gov/
nvpo/nvac as soon as it becomes
available.
The meeting will be held on
Friday, June 21, 2013, from 11:00 a.m.
to 12:00 p.m. EDT. This meeting will be
conducted utilizing a means of virtual
technology only.
ADDRESSES: This meeting will be
conducted only by audio conference
call.
DATES:
FOR FURTHER INFORMATION CONTACT:
National Vaccine Program Office,
Department of Health and Human
Services, Hubert H. Humphrey Building,
200 Independence Avenue SW.,
Washington, DC 20201. Telephone:
(202) 690–5566; Fax: (202) 690–4631;
Email address: nvpo@hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to Section 2102 of the Public Health
Service Act (42 U.S.C. 300aa–1), the
Secretary of Health and Human Services
was mandated to establish the National
Vaccine Program (NVP) to achieve
optimal prevention of human infectious
diseases through immunization and to
achieve optimal prevention against
adverse reactions to vaccines. NVAC
was established to provide advice and
make recommendations to the Director
of NVP on matters related to the
program’s responsibilities. The
Assistant Secretary for Health (ASH)
serves as Director of the NVP.
NVAC met on June 11–13, 2013. The
Committee’s discussion included its
intent to deliberate and vote on advice
to be given to the ASH on the proposed
rule from the Centers for Medicare and
Medicaid Services (CMS) to remove the
Immunization for Pneumonia Measure
(IMM–1) from the Inpatient Quality
Reporting Program. The comment
period for the proposed rule ends on
June 25, 2013. NVAC is not scheduled
to meet again before the end of the
comment period for the proposed rule.
Therefore, it has been decided that a
special meeting should be convened for
the NVAC to develop and discuss
recommendations to be submitted to the
ASH on the proposed rule. The
proposed rule is printed in the Federal
Register, Vol. 78. No. 91, Friday, May
10, 2013, pp. 27486–27823. It is also
available at https://
www.federalregister.gov/articles/2013/
05/10/2013-10234/medicare-programhospital-inpatient-prospective-paymentsystems-for-acute-care-hospitals-andthe:
E:\FR\FM\24JNN1.SGM
24JNN1
37818
Federal Register / Vol. 78, No. 121 / Monday, June 24, 2013 / Notices
Audio participation in this meeting is
available to the public. The following
information is provided for individuals
who wish to participate in this meeting
by telephone: Toll free number for calls
originating in the United States:
1–888–677–1385; Toll free number for
calls originating outside the United
States: 1–312–470–7133; the passcode
for all originating calls is 8094285.
Please note that this special meeting
is being held only to provide
opportunity for the NVAC to provide
recommendations to the ASH on
comments to be given to CMS on the
proposed rule. A decision was made at
the meeting most recently held by
NVAC on June 11–12, 2013, that the
Committee should make
recommendations to the ASH on the
proposed rule. Comments on the
proposed rule are due to be submitted
to CMS no later than June 25, 2013. The
number of days between the recent
NVAC meeting and the due date for the
comments to CMS is less than 15 days.
Therefore, notice to the public about the
NVAC being convened for this specific
purpose could not be published in the
Federal Register, as required by the
Federal Advisory Committee Act, 15
days prior to the date the special
meeting is scheduled to be held.
Dated: June 19, 2013.
Bruce Gellin,
Director, National Vaccine Program Office,
and Executive Secretary, National Vaccine
Advisory Committee.
[FR Doc. 2013–14996 Filed 6–21–13; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[CDC–2013–0011; NIOSH–262]
Request for Information on Toluene
Diisocyanates
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for Information.
mstockstill on DSK4VPTVN1PROD with NOTICES
AGENCY:
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) intends to
evaluate the scientific data on toluene
diissocyanate (TDI) and other TDI-based
isocyanate products to develop a
Criteria Document to establish an
updated Recommended Exposure Limit
VerDate Mar<15>2010
18:13 Jun 21, 2013
Jkt 229001
(REL) for toluene diisocyanate. The
current NIOSH REL for 2,4–TDI is the
lowest feasible concentration with no
ceiling due to the potential
carcinogenicity of 2,4–TDI.
NIOSH is requesting information on
the following: (1) Published and
unpublished reports and findings from
in vitro and in vivo toxicity studies with
toluene diisocyanate; (2) information on
possible health effects observed in
workers exposed to toluene
diisocyanate, including exposure data
and the method(s) used for sampling
and analyzing exposures; (3) description
of work tasks and scenarios with a
potential for exposure to toluene
diisocyanate; (4) information on control
measures (e.g. engineering controls,
work practices, personal protective
equipment, exposure data before and
after implementation of control
measures) that are being used in
workplaces with potential exposure to
toluene diisocyanate; and (5)
surveillance findings including
protocol, methods, and results.
DATES: Public Comment Period:
Comments must be received August 8,
2013.
ADDRESSES: You may submit comments,
identified by CDC–2013–0011 and
Docket Number NIOSH–262, by either
of the two following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C34, 4676
Columbia Parkway, Cincinnati, OH
45226.
Instructions: All information received
in response to this notice must include
the agency name and docket number
(CDC–2013–0011; NIOSH–262). All
relevant comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. All
electronic comments should be
formatted as Microsoft Word. Please
make reference to CDC–2013–0011 and
Docket Number NIOSH–262.
FOR FURTHER INFORMATION CONTACT:
Naomi Hudson, Dr.P.H., NIOSH, Robert
A Taft Laboratories, MS–C32, 4676
Columbia Parkway, Cincinnati, OH
45226, telephone (513) 533–8388.
SUPPLEMENTARY INFORMATION: Toluene
diisocyanates are colorless to pale
yellow liquids or solids with a sharp,
pungent odor. TDI is one of the most
commonly used diisocyanates. The most
common formulation of TDI is a mixture
of two isomers: 80% 2,4–TDI and 20%
2,6–TDI. Approximately 541 million
pounds of TDI were used in 2008, and
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
527 million pounds of TDI were used in
2010.
Occupational exposure occurs during
production and use of diisocyanates,
such as the mixing and foaming
processes in the polyurethane foam
industry, and during spray adhesive
application in the automobile and
furniture industries. TDI is an irritant to
the eyes, skin, and the gastrointestinal
and respiratory tracts. Workers exposed
to TDI may also be sensitized, such that
they might be subject to asthma attacks.
In 1996 NIOSH published a NIOSH
Alert, Preventing Asthma and Death
from Diisocyanate Exposure [DHHS
(NIOSH) Publication No. 96–111]. In
1989, NIOSH published a Current
Intelligence Bulletin on toluene
diisocyanate (TDI) and toluenediamine
(TDA) [DHHS (NIOSH) Publication No.
90–101] which classified TDI and TDA
(used in the manufacturing of TDI) as
potential occupational carcinogens.
The current NIOSH REL for 2,4–TDI
is the lowest feasible concentration with
no ceiling due to the potential
carcinogenicity of TDI. The OSHA
permissible exposure limit (PEL) for TDI
is 0.005 ppm, with a ceiling of 0.02
ppm. The American Conference of
Governmental Industrial Hygienists
(ACGIH) threshold limit value (TLV) for
TDI is 0.005 ppm with a ceiling of 0.02
ppm to minimize effects on the
respiratory tract and to minimize the
potential for sensitization.
NIOSH seeks to obtain materials,
including published and unpublished
reports and research findings, to
evaluate the possible health risks of
occupational exposure to diisocyanates.
Examples of requested information
include, but are not limited to, the
following:
(1) Identification of industries or
occupations in which exposures to TDI
may occur.
(2) Trends in the production and use
of TDI.
(3) Description of work tasks and
scenarios with a potential for exposure
to TDI.
(4) Workplace exposure measurement
data of TDI in various types of
industries and jobs.
(5) Case reports or other health
information demonstrating potential
health effects in workers exposed to
TDI.
(6) Research findings from in vitro and
in vivo studies.
(7) Information on control measures
(e.g., engineering controls, work
practices, PPE) being taken to minimize
worker exposure to TDI.
(8) Educational materials for worker
safety and training on the safe handling
of diisocyanates.
E:\FR\FM\24JNN1.SGM
24JNN1
]]>Agencies
[Federal Register Volume 78, Number 121 (Monday, June 24, 2013)]
[Notices]
[Pages 37817-37818]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14996]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the National Vaccine Advisory Committee
AGENCY: National Vaccine Program Office, Office of the Assistant
Secretary for Health, Office of the Secretary, Department of Health and
Human Services.
ACTION: Notice of a teleconference meeting.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (HHS) is hereby giving notice
that the National Vaccine Advisory Committee (NVAC) will be holding a
special meeting. This meeting will be held utilizing a means of virtual
technology; the meeting will be conducted as an audio telephone
conference call. The meeting will be open to the public. Individuals
may call in to attend this virtual meeting. A public comment session
will be provided. Participation in this meeting is limited to 60
people. Therefore, pre-registration is required for both public
participation and comment. Individuals who wish to participate in the
meeting by audio telephone conference call and/or provide public
comment should pre-register by sending an email to nvpo@hhs.gov or
calling (202) 690-5566. Individuals will be required to provide their
name, organization, and email address to pre-register. The meeting
agenda will be posted on the NVAC Web site at https://www.hhs.gov/nvpo/nvac as soon as it becomes available.
DATES: The meeting will be held on Friday, June 21, 2013, from 11:00
a.m. to 12:00 p.m. EDT. This meeting will be conducted utilizing a
means of virtual technology only.
ADDRESSES: This meeting will be conducted only by audio conference
call.
FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office,
Department of Health and Human Services, Hubert H. Humphrey Building,
200 Independence Avenue SW., Washington, DC 20201. Telephone: (202)
690-5566; Fax: (202) 690-4631; Email address: nvpo@hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant to Section 2102 of the Public
Health Service Act (42 U.S.C. 300aa-1), the Secretary of Health and
Human Services was mandated to establish the National Vaccine Program
(NVP) to achieve optimal prevention of human infectious diseases
through immunization and to achieve optimal prevention against adverse
reactions to vaccines. NVAC was established to provide advice and make
recommendations to the Director of NVP on matters related to the
program's responsibilities. The Assistant Secretary for Health (ASH)
serves as Director of the NVP.
NVAC met on June 11-13, 2013. The Committee's discussion included
its intent to deliberate and vote on advice to be given to the ASH on
the proposed rule from the Centers for Medicare and Medicaid Services
(CMS) to remove the Immunization for Pneumonia Measure (IMM-1) from the
Inpatient Quality Reporting Program. The comment period for the
proposed rule ends on June 25, 2013. NVAC is not scheduled to meet
again before the end of the comment period for the proposed rule.
Therefore, it has been decided that a special meeting should be
convened for the NVAC to develop and discuss recommendations to be
submitted to the ASH on the proposed rule. The proposed rule is printed
in the Federal Register, Vol. 78. No. 91, Friday, May 10, 2013, pp.
27486-27823. It is also available at https://www.federalregister.gov/articles/2013/05/10/2013-10234/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the:
[[Page 37818]]
Audio participation in this meeting is available to the public. The
following information is provided for individuals who wish to
participate in this meeting by telephone: Toll free number for calls
originating in the United States: 1-888-677-1385; Toll free number for
calls originating outside the United States: 1-312-470-7133; the
passcode for all originating calls is 8094285.
Please note that this special meeting is being held only to provide
opportunity for the NVAC to provide recommendations to the ASH on
comments to be given to CMS on the proposed rule. A decision was made
at the meeting most recently held by NVAC on June 11-12, 2013, that the
Committee should make recommendations to the ASH on the proposed rule.
Comments on the proposed rule are due to be submitted to CMS no later
than June 25, 2013. The number of days between the recent NVAC meeting
and the due date for the comments to CMS is less than 15 days.
Therefore, notice to the public about the NVAC being convened for this
specific purpose could not be published in the Federal Register, as
required by the Federal Advisory Committee Act, 15 days prior to the
date the special meeting is scheduled to be held.
Dated: June 19, 2013.
Bruce Gellin,
Director, National Vaccine Program Office, and Executive Secretary,
National Vaccine Advisory Committee.
[FR Doc. 2013-14996 Filed 6-21-13; 8:45 am]
BILLING CODE 4150-44-P
